Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet …
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Vaxart, Inc.'s gradings, price targets and earnings estimates. None
Reported
Past Estimate Consensus
Future Estimate Consensus
Vaxart, Inc. can't present any analysts estimates at the moment detail analysis.